ACEF | Compounding, pharmaceutical, personal care and nutraceutical ingredients

Reserved Area

New User

You still don’t have the access credentials for the Reserved Area? Sign up to access:
Register to have full access to confidential content

  • Technical and safety data sheets
  • Additional technical documents (for customers only)
  • Monographs and presentations
  • Test certificates (for customers only)
  • Price list and new formulation items (only for customer Pharmacies)

Sign in


Enter your credentials to log into the Reserved Area.


27 august 2020
Resveratrol and bone health
  • Date: 27/08/2020
  • Category: News ACEF Nutraceuticals

Share on:

Share on:

Share on:

“The results of the RESHAW clinical study point to how resveratrol helps improve the health of bones in subjects at risk for osteoporosis such as menopausal women.”

Resveratrol is a polyphenol of natural origin that has aroused particular interest in the scientific community owing to its marked antioxidant properties. Over 170 clinical studies have been published with the aim of assessing the ability of this substance to counter the adverse effects of ageing and the onset of age-related diseases.

Evolva, a Swiss biotech leader in the production of resveratrol from fermentation, has recently shared the results of the RESHAW clinical study (acronym for Resveratrol Supporting Healthy Ageing in Women): a controlled and randomised clinical trial lasting two years aimed at assessing the effects of regular resveratrol supplementation on a sample of 125 menopausal women aged between 45 and 85 years. The new publication, presented in July 2020 on the Journal for Bone and Mineral Research, points to the fact that resveratrol helps improve bone health in subjects at risk for osteoporosis such as menopausal women.

The volunteers who took part in the cross-over experiment were randomly divided into two groups and consecutively underwent two alternate treatments: for 12 months, one group took two 75mg capsules a day of Veri-te™ Resveratrol by Evolva, whereas the control group were treated with a placebo supplement, only containing inert excipients; in the 12 consecutive months the treatments of the two groups were inverted respectively.

The results of the study show how supplementation with Veri-te™ Resveratrol improves bone mineral density (BMD) in critical regions such as the lumbar area of the spine (+0.016 ± 0.003 g/cm2) and the neck of the femur (+0.005 ± 0.002 g/cm 2). In particular, attenuation in bone decline of the femoral neck results in a decreased risk of hip fracture in the following 10 years.

BMD improvement goes hand in hand with a 7.2% decrease of C-terminal telopeptide (CTX), a marker from type I collagen degradation; CTX decrease is greater in subjects who have more rapid bone resorption.

The statistical analysis of results also highlighted a positive synergy between resveratrol and vitamin D and/or calcium supplements: the benefits of resveratrol on the bone density of the spine and hip were found to be amplified in women who regularly took vitamin D and calcium-based supplements.

For more information click HERE and read the complete scientific publication.